Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVR - Bulls no Bears -- Ignore unavailable to you. Want to Upgrade?

To: garden_man who wrote (487)	5/7/1997 4:53:00 PM
From: garden_man	Respond to of 913

To All: Interesting piece of news from the WSJ: Promising AIDS Drugs By 2002, though the number of HIV-infected patients isn't expected to grow much, awareness of the disease will increase and we expect the number of patients under treatment to double," Dr. Rubin said. To keep pace with market growth, Glaxo is speeding development of two promising drugs, still known only by their research numbers 141W94 and 1592U89. As Glaxo's first entry in the hot new category of drugs known as protease inhibitors, 141W94 appears more potent than rival drugs and is free of food or drug interaction problems associated with rival products. Meanwhile, 1592U89 is a drug that works by jamming HIV replication by the same mechanism as Epivir and Retrovir -- but in early testing has reduced levels of the virus in patients' blood far more effectively than existing medicines. Equally important, both new drugs seem to have distinctive resistance profiles, which is a crucial characteristic for potential new AIDS medicines. The compounds will begin the final round of clinical trials later this year. If the tests are successful, Glaxo officials said applications to regulatory agencies can be submitted as early as next year. Though Glaxo traditionally has discovered most of the drugs it markets, the research pipeline currently includes a number of promising medicines licensed from other companies. Glaxo holds European rights to Romozin, a drug used to treat adult onset diabetes, discovered by Warner Lambert Co. Known generically as troglitazone, the drug has been a big success in the U.S. and could help plug the hole left by Zantac if, as most analysts expect, Glaxo gains regulatory approval later this year. Partnering is the key now for some of these large drug companies!